Medical device startup Level Zero Health (LZH) has raised £5.5m ($6.9m) in a pre-seed funding round for its hormone-tracking biosensor platform.
European venture capital firm Redalpine led the round, with contributions from HAX (SOSV) and Entrepreneur First (EF), among others.
Go deeper with GlobalData
Co-founded by CEO Ula Rustamova and chief technology officer (CTO) Irene Jia, LZH is focused on the technology that provides remote and continuous monitoring of hormone levels.
Its device uses DNA-based sensors to provide real-time hormone monitoring, is designed to be “minimally invasive” and can be worn on the skin.
The device can also correlate data with blood readings through interstitial fluid. It offers real-time updates on hormone levels, which can lead to immediate treatment adjustments, aiding in reproductive health management.
The company’s clinical advisory board includes fertility expert Aaron Styer from CCRM Fertility, Harvard Medical School; and Joshua Klein from Extend Fertility, Icahn School of Medicine at Mount Sinai.
With the new funding, LZH plans to pursue Food and Drug Administration (FDA) and CE mark approvals for its intermittent monitoring device, a crucial step towards bringing its product to market.
Additionally, the startup is expanding its research and development (R&D) efforts and scope of recruiting members in both the US and the UK to expedite product development.
Rustamova said: “Hormones are fundamental to how we live, yet the tools to understand them are decades behind.
“Our mission is to bridge this gap, empowering individuals and clinicians with real-time insights that have never before been possible.”
